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Summary
Background In sub-Saharan Africa, children are frequently admitted with severe anaemia needing an urgent blood 
transfusion, but blood is often unavailable. When conventional blood supplies are inadequate, allogeneic umbilical 
cord blood could be a feasible alternative. The aim of this study was to assess the safety and eﬃ  cacy of cord blood 
transfusion in children with severe anaemia.
Methods Between June 26, 2007, and May 20, 2008, 413 children needing an urgent blood transfusion were admitted 
to Kiliﬁ  District Hospital in Kenya. Of these, 87 children were eligible for our study—ie, younger than 12 years, 
no signs of critical illness, and haemoglobin 100 g/L or lower (if aged 3 months or younger) or 40 g/L or lower 
(if older than 3 months). Cord blood was donated at Coast Provincial General Hospital, Mombasa, and screened for 
transfusion-transmitted infections and bacterial contamination. Red blood cells were stored vertically at 2–6°C to 
enable sedimentation. After transfusion, children were monitored closely for adverse events and followed up for 
28 days. The primary outcome measure was the frequency and nature of adverse reactions associated with the 
transfusion. Secondary outcomes were the changes in haemoglobin concentrations 24 h and 28 days after transfusion, 
compared with pretransfusion levels. This trial is registered on ISRCTN.com, number ISRCTN66687527.
Findings Of the 87 children eligible for the study, cord blood was unavailable for 24, six caregivers declined consent, 
and two children were withdrawn before transfusion. Therefore, 55 children received umbilical cord red blood cells 
from 74 donations. Ten (18%) children had ten serious adverse events and 43 (78%) had 94 adverse events; the most 
frequent adverse events were anaemia (n=14), weight loss (n=12), and vomiting (n=10). An independent expert panel 
judged none of these adverse events to be probably or certainly caused by the cord blood transfusion (one-sided 
97·5% CI 0–6·5). Haemoglobin increased by a median of 26 g/L (IQR 21–31) 24 h after transfusion and by 50 g/L 
(10–68) a median of 29 days (28–35) after transfusion.
Interpretation These preliminary data suggest that cord blood could be an important supplementary source of blood 
for transfusion in children in sub-Saharan Africa. Further studies are needed to compare the safety and eﬃ  cacy of 
cord blood with conventional adult-donated blood for transfusions. Challenges associated with cost, infrastructure, 
and scale up also need investigating.
Funding Wellcome Trust.
Copyright © Hassall et al. Open access article distributed under the terms of CC BY.
Introduction
In Sub-Saharan Africa, babies in the ﬁ rst month of life 
have the highest risk of death, and the region has made 
little progress in reducing this high mortality rate.1 Severe 
anaemia is a major public health problem in sub-Saharan 
Africa, and children younger than 2 years are the most 
frequently aﬀ ected. The prevalence of severe anaemia in 
children in hospital is 8–29%, with case fatality ranging 
from 8% to 18%.2 In children with severe uncompensated 
anaemia, blood transfusion can reduce mortality substan-
tially.3 More than 50% of deaths happen within 4 h of 
admission, and early intervention and a source of safe 
blood are key components of the treatment of severe 
anaemia in childhood.4,5 Supply of conventional blood for 
trans fusion in sub-Saharan Africa is insuﬃ  cient, with 
only an estimated 52% of demand being met and a 
shortfall of at least 2 million units a year.6–8
In situations when blood supply is limited, or young 
children need a substantial number of transfusions, the 
umbilical cord is a novel and potentially important 
source of blood.9–11 Use of cord blood might not only 
enable an increase in the number of small-volume 
transfusions but also reduce pressure on stocks of 
conventional adult-donated blood, thereby augmenting 
supplies for emergency transfusions for other vulnerable 
groups. In sub-Saharan Africa, a scarcity of blood for 
transfusion is implicated in 25% of maternal deaths due 
to haemorrhage.12
To test the feasibility of cord blood transfusion, we have 
established a cord blood donation programme on the 
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labour ward at Coast Provincial General Hospital in 
Mombasa, Kenya. Previously, we have shown the 
acceptability to mothers of cord blood donation and 
transfusion, the feasibility of a two-stage informed 
consent process for cord blood donation, and the quality 
of variable volumes of whole cord blood stored in a ﬁ xed 
volume of anticoagulant preservative solution.13,14 We also 
reported that, for cord blood obtained by our study team, 
the frequency of both bacterial contamination and 
seroreactivity for HIV, hepatitis B and C viruses, and 
syphilis compare favourably with those for conventional 
adult blood donated to the regional blood transfusion 
centre in Mombasa.15 To our knowledge, we report here 
the ﬁ rst clinical trial of allogeneic cord blood transfusion 
in children with severe anaemia. The aim of our study 
was to assess the safety and eﬃ  cacy of umbilical cord red 
blood cell transfusion in children with severe anaemia.
Methods
Participants
We designed an open-label single-arm study with the aim 
to produce preliminary data for safety, harm, and 
haematological eﬃ  cacy of umbilical cord red blood cell 
transfusion in children with severe anaemia. We recruited 
children younger than 12 years who were admitted for 
paediatric care at Kiliﬁ  District Hospital, Kenya. 
We designed our eligibility criteria to identify children for 
whom a transfusion would provide clinical beneﬁ t, based 
on WHO clinical guidelines, but exclude those who were 
critically ill.16
Children were eligible for inclusion in the study if they 
had severe anaemia (haemoglobin ≤100 g/L in babies aged 
3 months or younger, or ≤40 g/L in children older than 
3 months) and the attending clinician requested a blood 
transfusion. We excluded children with any of these 
clinical features of critical illness: coma (Blantyre coma 
scale ≤2); prostration; shock; deep (acidotic) breathing; 
and hyperbilirubinaemia requiring exchange transfusion. 
Furthermore, we judged children ineligible for the study if 
they had received a previous cord blood transfusion as 
part of this trial or were already enrolled in another 
intervention trial. We only enrolled a child into the study if 
suﬃ  cient cord blood was available.
All caregivers of participating children gave written 
informed consent. The Kenyan national ethics committee 
and the research ethics committee of the Liverpool 
School of Tropical Medicine (UK) reviewed and approved 
the study protocol. 
Procedures
We obtained cord blood from placentas donated at Coast 
Provincial General Hospital in Mombasa. We screened 
all donations for HIV, hepatitis B and C viruses, and 
syphilis, as described previously.15 All samples were 
quarantined until they were screened for bacterial 
contamination, which we did by incubating a 4 mL 
sample of cord blood in 40 mL of brain-heart infusion at 
37°C for 48 h, as described previously.15,17 Screening was 
by microscopic examination of a Gram-stained smear. 
We transported units of screened cord blood by road to 
Kiliﬁ  (a distance of 50 km) at 2–6°C. We stored samples 
vertically in racks at 2–6°C to enable sedimentation of red 
blood cells.
We used an electronic database to record the volume, 
haemoglobin concentration, and blood group of cord 
blood units. As soon as a blood transfusion was 
requested for an eligible child, we referred to this 
database to ascertain whether suﬃ  cient cord blood was 
available. The hospital clinical laboratory at Kiliﬁ  District 
Hospital used standard methods for blood grouping 
and cross-matching. At least 2·2 g/kg of haemoglobin 
was required for transfusion from a maximum of 
two group-identical or group-compatible cord blood 
units. Thus, we selected cord blood units based on 
estimated haemo globin content, rather than volume. 
Furthermore, no child received a transfusion with more 
than 3·5 mL/kg of the preservative citrate phosphate 
dextrose adenine (CPDA-1).
Research staﬀ  from the Kenya Medical Research 
Institute (KEMRI)/Wellcome Trust research programme 
provided 24 h clinical cover at Kiliﬁ  District Hospital on 
the paediatric wards and paediatric high-dependency 
unit. At admission, all children underwent structured 
clinical assessment, including anthropometric measure-
ments and standard laboratory investigations, such as 
estimation of haemoglobin concentration (Beckman 
Coulter, Villepinte, France), a blood ﬁ lm examination for 
malaria, and blood culture. We did haemoglobin 
electrophoresis retrospectively to detect haemoglobin S in 
children older than 3 months. Full investigation of the 
cause of severe anaemia was not part of the study protocol.
Before the cord blood transfusion, and for a period of 
24 h afterwards, we admitted children to the paediatric 
high-dependency unit. In children with severe acute 
malnutrition (deﬁ ned as a weight-for-height Z score less 
than –3 in children older than 3 months), we transfused 
umbilical cord red blood cells over a period of 3 h with a 
maximum permitted volume of 10 mL/kg, and we 
administered 1 mg/kg of furosemide intravenously at 
the start of the transfusion, according to clinical 
guidelines.16 For children without severe acute 
malnutrition, we transfused umbilical cord red blood 
cells over a period of 4 h with a maximum permitted 
volume of 20 mL/kg, and we did not administer 
furosemide.
For the ﬁ rst 2 h of the cord blood transfusion, we did 
continuous physiological monitoring. We recorded 
temperature, pulse rate, respiration rate, oxygen 
saturation, and blood pressure before transfusion, 15 min 
after the start, and every 30 min thereafter. After 2 h, we 
obtained a blood sample to estimate serum potassium 
(iLyte ion selective electrode analyser; Instrumentation 
Laboratory, USA) and calcium (Selectra E; Vital Scientiﬁ c, 
Netherlands). We took a blood sample for haemoglobin 
For the study protocol see 
https://globalresearchmethods.
tghn.org/methodology-projects/
umbilical-cord-blood-
transfusion-trial
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estimation 24 h after the start of the cord blood 
transfusion, unless a haemoglobin measurement was 
requested for clinical management of the child before 
this time, in which case we used this result. We obtained 
a further blood sample for haemoglobin estimation from 
children who returned for follow-up after 28 days.
When a child was discharged from hospital, we gave 
their caregiver the cost of the fare home and the return 
fare back to the hospital, and we invited the caregiver to 
bring the child to the hospital 28 days after the cord blood 
transfusion. We encouraged them to come back to the 
hospital before then if they had any concerns about their 
child. We recorded details of the location of the child’s 
home. Children who returned to hospital at 28 days had a 
structured clinical assessment. For those who did not 
attend hospital, a ﬁ eldworker followed up at home, 
conﬁ rming whether the child was alive and well by either 
direct observation or discussion with an adult family 
member; caregivers were also encouraged to bring their 
child to the hospital for a full review.
Detection of adverse reactions was a two-stage process 
comprising rigorous surveillance of adverse events 
(monitoring of harm) and an independent expert 
judgment about the relation of the adverse event to the 
umbilical cord red blood cell transfusion (assessment of 
imputability). To capture adverse events, a clinician 
reviewed every child and did a study-speciﬁ c structured 
clinical assessment 2 h after the end of the transfusion, 
24 h after the end of the transfusion, and at discharge 
from hospital. For the remainder of the child’s time in 
hospital, monitoring of harm was by review of the daily 
clinical record kept by the attending clinicians. We 
deﬁ ned serious adverse reactions as any serious adverse 
event (ie, any untoward medical occurrence that is fatal, 
life-threatening, disabling, prolongs admission, or 
results in admission)18 that was judged probably or 
certainly related to the transfusion. We deﬁ ned adverse 
reactions as any adverse event (ie, any untoward medical 
occurrence)18 judged probably or certainly related to the 
transfusion.
The principal investigator (OWH) and an independent 
local safety monitor (a skilled consultant paediatrician) 
reviewed all serious adverse events and prepared a case 
summary, which was sent to the safety review committee. 
This committee consisted of three paediatricians who 
were independent of the study, with extensive experience 
of the clinical care of children in sub-Saharan Africa. 
The safety review committee and the local safety monitor 
reached consensus about the probability that a serious 
adverse event was caused by the transfusion of umbilical 
cord red blood cells and assigned the event an 
imputability score based on an established four-point 
scale, ranging from unlikely (0) to certain (3).19 A study 
clinician (FH) and the principal investigator (OWH) 
reviewed all other (non-serious) adverse events, which 
were described according to an established adverse 
reaction nomen clature.20 They used the same four-point 
imputability scale19 to score the probability of a causative 
relation of an adverse event with umbilical cord red blood 
cell trans fusion. A summary of these adverse events was 
reviewed by a safety review committee and the local 
safety monitor.
The trial was to be stopped in the event of a suspected 
unexpected serious adverse reaction and not recommenced 
until a full review had been undertaken by the safety 
review committee and their recommendations seen and 
approved by both research ethics committees. Moreover, 
Figure: Study proﬁ le 
413 transfusions to children 
105 aged ≤3 months 
  
308 aged >3 months 
12 had haemoglobin 
>100 g/L 
93 had haemoglobin 
≤100 g/L 
114 had haemoglobin 
≤40 g/L 
44 outpatient 
follow-up 
194 had haemoglobin 
>40 g/L
11 community 
follow-up 
207 children eligible for study 
by haemoglobin criterion 
87 children eligible by
clinical criteria 
120 children ineligible by
clinical criteria 
24 cord blood unavailable
6 declined consent 
 
57 children enrolled 
55 children had cord-blood
transfusion 
2 children withdrawn
before transfusion 
Infants aged 
≤3 months
(n=24)
Infants aged 
>3 months
(n=31)
Total
(n=55)
Girls/boys 12/12 15/16 27/28
Sickle-cell genotype SS .. 6 6
Malaria parasites present 0 6 6
Weight-for-height Z score less than –3 .. 7 7
Preterm* 14 .. 14
Weight (kg) 1·6 (1·1–4·9) 8·6 (4·7–14·5) 5·3 (1·1–14·5)
Pretransfusion haemoglobin concentration (g/L) 87 (55–100) 32 (19–40) 40 (19–100)
Data are either number of participants or median (range). *Born before 37 weeks of pregnancy was completed.
Table 1: Selected characteristi cs of children at admission
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in the event of a serious adverse event, the safety review 
committee advised whether they felt that the trial should 
continue with no change to the protocol, continue with a 
change to the protocol, or be stopped.
Outcomes
The primary outcome measure was the frequency 
and nature of adverse reactions occurring during or 
within at least 28 days of the umbilical cord red blood 
cell transfusion. The secondary outcome measure was 
the median change from pretransfusion levels in 
haemoglobin concentrations 24 h and 28 days after cord 
blood transfusion.
In the event of an adverse reaction after a cord blood 
transfusion (which comprised a maximum of two blood 
units), imputability could not be assigned to one of the two 
units. Therefore, the denominator for the primary outcome 
was the number of children receiving a transfusion. 
Children who received a subsequent conventional blood 
transfusion during the follow-up period were included in 
the analysis of the primary outcome, because these 
transfusions could themselves be evidence of harm related 
to a cord blood transfusion. However, children receiving a 
conventional blood transfusion were not included in the 
analysis of haemoglobin change at 28 days, because 
subsequent transfusions would have confounded the 
eﬀ ect of the cord blood transfusion.
Statistical analysis
We estimated from previous data that 100 children 
fulﬁ lling the eligibility criteria for the trial would be 
admitted to Kiliﬁ  District Hospital during a period of 
1 year and that cord blood would be available and consent 
for a transfusion given for 40–80% of these children. 
Thus, during 1 year of study, 40–80 children might be 
recruited to the trial. We intended to run the trial for 
1 year; therefore, we set these numbers as a minimum 
and maximum sample size. The appendix (p 1) shows 
estimates for the frequency of adverse reactions at these 
minimum and maximum sample sizes.
We expressed binary data as a percentage with 95% CIs 
where appropriate. When event frequencies were zero, 
we calculated a one-sided 97·5% CI with a lower limit of 
zero. We summarised continuous data with medians and 
range or IQR. We compared noted diﬀ erences in 
continuous data with non-parametric statistics (Wilcoxon 
rank-sum test).
This trial is registered on ISRCTN.com, number 
ISRCTN66687527.
Role of the funding source
The funder had no role in study design, data collection, 
data analysis, data interpretation, or writing of the 
report. The corresponding author had full access to all 
data in the study and had ﬁ nal responsibility for the 
decision to submit for publication.
Results
Between June 26, 2007, and May 20, 2008, 413 children 
admitted to Kiliﬁ  District Hospital, Kenya, needed a 
blood transfusion; of these, 87 were eligible for our trial 
(ﬁ gure). An umbilical cord red blood cell donation of 
either suﬃ  cient haemoglobin content or the correct 
blood group was unavailable for 24 children, and the 
caregiver declined consent for six children. Thus, 
57 children were recruited to the study. Two participants 
were withdrawn before umbilical cord red blood cell 
Before 
transfusion
Within 24 h From 24 h to 
28 days
Age ≤3 months
Number of children 24 24 13
Haemoglobin concentration (g/L) 87 (78–92) 114 (105–124) 92 (84–99)
Change in haemoglobin concentration (g/L) ·· 27 (22–38) 5 (2–12)
Age >3 months
Number of children 31 31 20
Haemoglobin concentration (g/L) 32 (27–38) 58 (53–62) 93 (83–110)
Change in haemoglobin concentration (g/L) ·· 26 (21–31) 61 (53–82)
All children
Number of children 55 54* 33†
Haemoglobin concentration (g/L) 40 (31–82) 65 (57–113) 90 (84–102)
Change in haemoglobin concentration (g/L) ·· 26 (21–31) 50 (10–68)
Data are median (IQR), unless otherwise stated. *Excludes one child for whom consent for a blood test was declined. 
†Excludes 22 children: ten received further transfusions; 11 were followed up in the community; and one was not bled 
in error.
Table 2: Haemoglobin concentration in children receiving umbilical cord red blood cell transfusions, 
stratiﬁ ed by age
Serious adverse 
events (n=10)
Adverse events 
(n=94)
Children (n) 10 43
Event timing
Before transfusion 4 4
During transfusion and within 
24 h afterwards
1 12
From 24 h to 28 days after 
transfusion
5 78
Indicator of severity
Fatal 1 N/A
Life-threatening 7 N/A
Admission 2 N/A
Imputability level*
Not assessable 0 0
Excluded (0) 4 15
Unlikely (0) 3 76
Possible (1) 3 3
Likely/probable (2) 0 0
Certain (3) 0 0
N/A=not applicable. *Numbers in parentheses refer to four-point imputability score.
Table 3: Serious adverse events and adverse events in children receiving 
umbilical cord red blood cell transfusions
See Online for appendix
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transfusion. In one case, the laboratory made an error 
during compatibility testing and no further cord blood 
was available. In the second case, clinical review soon 
after recruitment showed deep breathing, which was an 
exclusion criterion.
55 children received umbilical cord red blood cells 
from 74 cord blood donations. Of these, 24 children 
were aged 3 months or younger and 31 were older than 
3 months (table 1); the median age of children in the 
study was 12 months (range 2 days to 5 years 8 months). 
Children weighed between 1·1 kg and 14·5 kg (median, 
5·3 kg). The median weight-for-height Z score was 
1·9 (range –4·4 to –0·9), and seven children had severe 
acute malnutrition. All children with severe acute 
malnutrition received 10 mL/kg of umbilical cord red 
blood cells; for those without severe acute mal nu-
trition, the median volume transfused was 14 mL/kg 
(range 10–20).
In children aged 3 months or younger, pretransfusion 
haemoglobin was a median of 87 g/L (range 55–100, 
IQR 78–92). In children older than 3 months, median 
pretransfusion haemoglobin was 32 g/L (range 19–40, 
IQR 27–38). In all children, within a median of 24 h 
(IQR 17–24) of the cord blood transfusion, haemo globin 
had risen by a median of 26 g/L (IQR 21–31; table 2). 
33 children did not receive a further transfusion; after 
median follow-up of 29 days (IQR 28–35), the median 
rise in haemoglobin was 50 g/L (IQR 10–68). In children 
aged 3 months or younger, haemoglobin rose by a 
median of 5 g/L (IQR 2–12) at a median of 29 days 
(28–36) of follow-up, compared with a median increase 
of 61 g/L (53–82) in children older than 3 months 
(median follow-up 30 days [28–35]; p<0·0001).
In the seven children with severe acute malnutrition 
(all older than 3 months), who received a maximum of 
10 mL/kg umbilical cord red blood cells, the median rise in 
haemoglobin 24 h after transfusion was 21 g/L (IQR 20–29). 
In 24 children older than 3 months without severe acute 
malnutrition, who received between 10 mL/kg and 
16 mL/kg umbilical cord red blood cells (median 13 mL/kg), 
the median rise in haemoglobin 24 h after transfusion was 
26 g/L (IQR 22–31; p=0·15). Five of seven children with 
severe acute malnutrition had haemoglobin measured at 
28-day follow-up; the median rise in haemoglobin in this 
subgroup was 81 g/L (IQR 78–82), compared with 59 g/L 
(IQR 53–68) in 15 of 24 children without severe acute 
malnutrition for whom haemoglobin concentration was 
measured at follow-up.
Of the 55 children who received an umbilical cord red 
blood cell transfusion, ten had a serious adverse event 
(one event per child) and 43 children had 94 adverse 
events (table 3; appendix p 2) The most frequent adverse 
events were anaemia (n=14), weight loss (n=12), and 
vomiting (n=10). In no case was transfusion of umbilical 
cord red blood cells judged probably or certainly implicated 
and, thus, the frequency of serious adverse reactions and 
adverse reactions was 0% (one-sided 97·5% CI 0–6·5).
Of the ten serious adverse events recorded, four were 
new signs of critical illness (deep breathing or prostration) 
noted during the pretransfusion assessment, before 
Time after transfusion, 
and description of serious 
adverse event
Indicator of 
severity
Comments Imputability 
level (score)
Girl, aged 
13 months
Acute leukaemia, probably 
acute lymphoblastic leukaemia
Fatal Diagnosis of leukaemia made by microscopic examination of a peripheral blood ﬁ lm taken before cord 
blood transfusion but reported afterwards; child was referred to regional hospital but discharged 
against medical advice and taken home; child was pale, sick-looking, and febrile at discharge; child’s 
grandfather reported she died the day after arriving home, about 1 week after cord blood transfusion
Unlikely (0)
Boy, aged 2 days At 7 days, abdominal 
distension, respiratory distress, 
jaundice
Life-threatening Infant was born preterm (estimated gestation, 30 weeks; birthweight, 1440 g) with probable neonatal 
sepsis; full recovery after intervention with broad-spectrum antibiotics, nil by mouth, intravenous ﬂ uid, 
and phototherapy
Unlikely (0)
Boy, aged 4 years At 28 days, anaemia Admission Child had known sickle-cell disease; was discharged well 3 days after cord blood transfusion 
(haemoglobin 62 g/L) with haematinics; returned for follow-up at 21 days (haemoglobin 66 g/L); 
at 28-day follow-up, haemoglobin was 41 g/L; child admitted for conventional blood transfusion; 
discharged next day (haemoglobin 61 g/L)
Unlikely (0)
Boy, aged 24 days After 26 h, diarrhoea, 
dehydration, and metabolic 
acidosis
Life-threatening Preterm infant (estimated gestation, 28 weeks; birthweight, 1080 g) with probable neonatal sepsis; 
full recovery after intervention with oxygen, broad-spectrum antibiotics, and intravenous ﬂ uid
Possible (1)
Girl, aged 9 days After 14 h, sepsis, pneumonia, 
and apnoea events
Life-threatening Preterm infant (estimated gestation, 30 weeks; birthweight, 1200 g); pneumonia was conﬁ rmed by 
radiography; full recovery after intervention with broad-spectrum antibiotics, oxygen, aminophylline, 
and blood transfusion
Possible (1)
Girl, aged 5 days At 28 days, anaemia Admission Baby had a low birthweight (probable prematurity), neonatal jaundice, and possible sepsis; was 
discharged well 3 days after cord blood transfusion (haemoglobin 115 g/L); at 28-day follow-up, 
haemoglobin was 62 g/L; admission oﬀ ered but declined; child presented again 1 week later and was 
admitted (haemoglobin 84 g/L); conventional blood transfusion given once donor found (initially no 
blood available); discharged next day with haematinics
Possible (1)
Ages of children are at enrolment to the study. 
Table 4: Serious adverse events within 1 month of umbilical cord red blood cell transfusion
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transfusion of umbilical cord red blood cells. Therefore, 
the cord blood transfusion was excluded as a potential 
cause of these serious adverse events. Of the remaining 
six serious adverse events, one child died, three events 
were judged life-threatening, and two resulted in 
admission after discharge (table 4).
Discussion
Our ﬁ ndings show that, in a population of children from 
Kenya who were admitted to hospital with severe 
anaemia, transfusion of sedimented red blood cells from 
umbilical cord donations was safe and eﬃ  cacious. 
No serious adverse events or adverse events were 
certainly or probably attributable to cord blood trans-
fusion. Further more, the haemoglobin concen tra tion 
after transfusion rose by 26 g/L after 24 h and by 50 g/L 
at about 28 days. Our ﬁ ndings accord with previous 
scant data for allogeneic cord-blood transfusion.9
Although we excluded children with signs of critical 
illness at the time of study recruitment, adverse events 
were recorded in many participants, which were 
unrelated to the cord blood transfusion. In four children, 
signs of critical illness were detected at the clinical 
assessment undertaken just before cord blood trans-
fusion. To withdraw these critically ill children from the 
study at that stage, and to secure and cross-match adult-
donated blood, would have introduced an unacceptable 
delay in their management. This diﬃ  culty highlights 
the challenge of undertaking studies focusing on safety 
and harm in children admitted to hospital in sub-
Saharan Africa. Robust monitoring frameworks are 
needed to identify potential associations between the 
eﬀ ects of an intervention and other confounding 
factors. A weakness of our study is that, for children 
who did not attend the hospital for follow-up at 28 days, 
no structured clinical assessment was done. However, 
all children were followed up in the community by a 
non-clinical ﬁ eldworker, and the death of one participant 
was identiﬁ ed in this way.
The rise in haemoglobin recorded 24 h after cord 
blood transfusion (median 26 g/L) accords with 
estimates based on the haemoglobin content of 
transfused blood and the circulating volume of children: 
for a child with a circulating volume of 80 mL/kg, 
transfusion of 2·2 g/kg of haemoglobin might be 
expected to raise the haemoglobin concentration by 
28 g/L. However, although cord blood units were 
selected for transfusion based on an estimation of the 
unit haemoglobin content, we cannot ascertain from 
these data how much haemoglobin was actually issued 
and transfused.
The signiﬁ cant rise in haemoglobin 28 days after 
transfusion in children older than 3 months, compared 
with infants aged 3 months or younger, accords with 
previous data from Kiliﬁ  and other sites in east 
Africa.3,4,21,22 However, increases in haemoglobin over a 
similar period have also been seen in children with 
severe anaemia who do not receive a transfusion,3,21,22 
which highlights the importance of other strategies to 
manage severe anaemia—eg, treatment of infection, use 
of anthelmintics and haematinics, and diet. The relative 
importance of these interventions will depend on the 
cause of anaemia, which we did not investigate here.
Infants younger than 3 months in our study were likely 
to have very diﬀ erent reasons for their anaemia compared 
with the older children—eg, many infants were presumed 
to have anaemia of prematurity. Several of these children 
needed further blood transfusions and, in those who did 
not, the eﬀ ect of one umbilical cord red blood cell 
transfusion at 28 days was much more modest (5 g/L). 
However, the number of young infants who were eligible 
for a cord blood transfusion is noteworthy. This group of 
patients has a high burden of mortality in sub-Saharan 
Africa and potentially might beneﬁ t substantially from 
more evidence about the role of transfusion in prevention 
of high death rates.1 These young children might beneﬁ t 
in particular from the availability of cord blood for 
transfusion, because they only need small volumes 
of blood.
The microbiological safety of cord blood provided by 
the donation programme that we have established at 
Coast Provincial General Hospital in Mombasa 
compares favourably with that of conventional blood 
from the same setting.15 Mothers who donate their 
infants’ umbilical cord blood are selected rigorously 
(including self-reporting of antenatal testing for 
syphilis and HIV), and aseptic cord blood collection is 
done by trained ﬁ eldworkers and not the midwives who 
Panel: Research in context
Systematic review
A review of published work relating to cord blood transfusion was done before the study 
(April, 2007) and repeated before submission (September, 2014). We searched PubMed with 
the following search query: (“cord blood”[Title/Abstract] OR “placental blood”[Title/
Abstract] AND “transfusion”[Title/Abstract]); we did not restrict by date, language, or article 
type. The reference lists of articles identiﬁ ed were also screened for relevant titles. Allogeneic 
cord blood transfusion was ﬁ rst reported in the 1930s, before the advent of modern blood 
transfusion services.23 Subsequently, most research and clinical activity relating to cord blood 
transfusion has concerned autologous cord blood transfusion in preterm neonates.11 In 
India, a series of about 200 mainly elderly patients with chronic and terminal disease has 
received allogeneic cord blood transfusions.9,11 No adverse reactions were reported. To our 
knowledge, our study is the ﬁ rst clinical trial of allogeneic cord blood transfusion in children.
Interpretation
In children with severe anaemia in sub-Saharan Africa, transfusion of sedimented red blood 
cells obtained from umbilical cord blood has a low probability of adverse events. 
Haemoglobin recovery after cord blood transfusion is within expected limits. Umbilical cord 
blood could be a safe and eﬃ  cacious supplementary source of blood for transfusion when 
demand for low-volume transfusions for children is high and supplies of conventional 
blood are limited. Further work needs to be undertaken by clinical researchers to establish 
the safety and eﬃ  cacy of cord blood transfusion compared with conventional blood 
transfusion. Additional research is also needed on the operational aspects of cord blood 
collection, including costs, the eﬀ ect on conventional blood supply, and scalability.
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manage the deliveries.14,15 Furthermore, all cord blood 
donations in this study were screened for bacterial 
contamination. These rigorous techniques can be 
diﬃ  cult to replicate outside of a research setting 
without additional resources.
Our ﬁ ndings suggest that further trials of umbilical cord 
red blood cell transfusions are warranted (panel), but the 
challenges of doing such trials and the barriers to potential 
scale up of such an intervention should not be under-
estimated. Attributing eﬀ ects to the intervention is 
diﬃ  cult in such a sick group of children. Despite this 
limitation, further clinical trials should also include 
children with signs of critical illness who potentially have 
the most to gain from an improved blood supply. The 
infrastructure and training needed to set up collection and 
administration of umbilical cord blood is complex, and 
such trials would need meticulous monitoring during and 
after the transfusion. Poor haemovigilance systems in 
these settings means that very little is known about the 
harms associated with conventional blood transfusion, 
which would be the comparator group in such trials.7
Several improvements and additions could be made to 
the design of future trials. Better characterisation of the 
cause of anaemia could be included, in addition to 
assessment of any correlation with beneﬁ ts and 
harms of cord blood transfusion. Immunological and 
genetic testing could be done to compare rates of 
alloimmunisation and microchimerism. Finally, opera-
tional analyses could be done to compare the availability 
of cord blood and adult-donated blood for urgent 
transfusion in children and to look at how using 
cord blood for transfusions in children aﬀ ects the 
blood supply for adults who need larger volumes of 
transfused blood.
In settings where demand for low-volume transfusions 
for children is high and supplies of conventional blood 
are low, umbilical cord blood could be a safe and 
eﬀ ective supplementary source of blood for transfusion. 
Further trials comparing cord blood with conventional 
adult-donated blood transfusions are merited.
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